A relação entre os bifosfonatos e a osteonecrose

##plugins.themes.bootstrap3.article.sidebar##

PDF
Publicado Apr 29, 2023
DOI https://doi.org/10.25248/reaodonto.e12536.2023

##plugins.themes.bootstrap3.article.main##

Vitor Rodrigues da Silva
Alex de Sousa Libarino
Vinícius do Amaral Santos
Antonio Carlos Lourenço Guedes
Uninassau
Rita de Cássia Dias Viana Andrade

Resumo

Objetivo: Descrever a relação entre bifosfonatos e osteonecrose na Odontologia. Revisão bibliográfica: A osteonecrose induzida pelo uso contínuo dos bifosfonatos é uma enfermidade patológica que tem como característica principal o surgimento de uma área com exposição óssea exposta na cavidade bucal. American Association of Oral and Maxillofacial Surgeons orienta aos profissionais de saúde envolvidos no tratamento da osteonecrose mandibular em estágios iniciais (I) a terapêutica se consista na utilização de enxaguantes bucais antissépticos e antibióticos para controle da infecção. Em estágios avançados (II e III) o tratamento mais invasivo é recomendado. O diagnóstico em estágio inicial da osteonecrose mandibular com um plano de tratamento adequado para o caso em questão poderá ser mais benéfico para o paciente em comparação com um diagnóstico da enfermidade em estágios avançados. No entanto, cada circunstância necessita ser tratada de forma individualizada. Considerações finais: O diagnóstico na fase inicial da osteonecrose, juntamente com um plano de tratamento adequado será benéfico ao paciente, devido o tratamento se persistir de forma mais conservadora.

##plugins.themes.bootstrap3.article.details##

Como Citar
SilvaV. R. da, LibarinoA. de S., SantosV. do A., GuedesA. C. L., & AndradeR. de C. D. V. (2023). A relação entre os bifosfonatos e a osteonecrose. Revista Eletrônica Acervo Odontológico, 5, e12536. https://doi.org/10.25248/reaodonto.e12536.2023
Edição
v. 5 (2023): Revista Eletrônica Acervo Odontológico (ISSN 2674-7200) | Volume 5 | 2023
Seção
Artigos

Copyright © | Todos os direitos reservados.

A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.

Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.

Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.

Referências

1. BETH T, et al. Interventions for managing medication-related osteonecrosis of the jaw (Review) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. Cochrane Library, 2017; CD012432: 10(1–56).

2. DURÁN JÁC, et al. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). Journal of Clinical and Experimental Dentistry, 2017; 9(8): e1051–e1059.

3. CEPONIS P, et al. Hyperbaric oxygen therapy and osteonecrosis. Oral Diseases, 2017; 23(2): 141–151.

4. DUNPHY L, et al. Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. BMJ Case Reports, 2020; 13: 1.

5. EGUIA A, et al. Review and update on drugs related to the development of osteonecrosis of the jaw. 2020; 25: 1.

6. ENDO Y, et al. Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Biological and Pharmaceutical Bulletin, 2017; 40(6): 739–750.

7. GOODDAY RH. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw. Oral and Maxillofacial Surgery Clinics of North America, 2015; 27(4): 527–536.

8. GUPTA A, et al. Rehabilitation of Edentulism and Mortality: A Systematic Review. Journal of Prosthodontics, 2019; 28(5): 526–535.

9. HADZIC S, et al. Importance of Early Detection of Potentially Malignant Lesions in the Prevention of Oral Cancer. Materia Socio Medica, 2017; 29(2): 129.

10. HENIEN M, et al. Spontaneous osteonecrosis of the maxilla. Dental Update, 2016; 43(6): 563–566.

11. KHALFI L, et al. Osteonecrosis Mandibular Extended to Bisphosphonates: A Very Rare Extensive Case. Cureus, 2020; 12(3).

12. KHAN AA, et al. J BMR Diagnosis and Management of Osteonecrosis of the Jaw : A Systematic Review and International Consensus, 2015; 30(1): 3–23.

13. KUROSHIMA S, et al. Medication-related osteonecrosis of the jaw: A literature review. Journal of Oral Biosciences, 2019; 61(2): 99–104.

14. KUŹNIK A, et al. Bisphosphonates—much more than only drugs for bone diseases. European Journal of Pharmacology, 2020; 866.

15. MENDES V, et al. Impact of bisphosphonate therapy on dental implant outcomes : An overview of systematic review evidence. International Journal of Oral & Maxillofacial Surgery, 2018.

16. MIGLIORATI CA, et al. Medication-Related Osteonecrosis of the Jaws. Journal of the National Cancer Institute - Monographs, 2019; 53: 107–115.

17. MÜCKE T, et al. Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review. 2016; 1: 212.

18. OBINATA K, et al. Image findings of bisphosphonate related Osteonecrosis of the Jaws comparing with osteoradionecrosis. Dentomaxilofac Radiol., 2017; 46(5): 20160281.

19. OMAMI G, Medication-Related Osteonecrosis of the Mandible. Ear, Nose and Throat Journal, 2020; 2–3.

20. ROSELLA D, et al. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. Journal of International Society of Preventive and Community Dentistry, 2016; 6(2): 97–104.

21. ROSINI S, et al. Understanding bisphosphanates and osteonecrosis of the jaws: uses and riskd. 2015; 3309–3317.

22. RUGGIERO SL, Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw. Oral and Maxillofacial Surgery Clinics of North America, 2015; 27(4): 479–487.

23. SALEHI B, et al. Plant-derived bioactives in oral mucosal lesions: A key emphasis to Curcumin, Lycopene, chamomile, aloe Vera, green tea and coffee properties. Biomolecules, 2019; 9(3).

24. SANTOS M, et al. Extensive osteonecrosis of the maxilla caused by bisphosphonates: Report of a rare case. Journal of Clinical and Experimental Dentistry, 2019; 11(2): e203–e207.

25. SHIM Y, et al. Analysis of Factors Associated with the Postoperative Healing of Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis. 2021.

26. SILVA LF, et al. Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. 2015.

27. SMITH JD, et al. Maxilla Osteonecrosis: A Differential Diagnosis in Patients with Metastatic Cancer on Bisphosphonates. Journal of Case Reports in Medicine, 2016; 5: 1–3.

28. SPANOU A, et al. Management of bisphosphonate-related osteonecrosis of the jaw: A literature review. Oral Diseases, 2015; 21(8): 927–936.

29. STEINER C, Schleimhauterkrankungen: Differenzial diagnostischer zugang aus kieferchirurgischer sicht. Hautarzt, 2016; 67(10): 816–821.

30. VILLA A, et al. Leukoplakia—A Diagnostic and Management Algorithm. Journal of Oral and Maxillofacial Surgery, 2017; 75(4): 723–734.

31. WALKER AW. Microbiota of the Human Body, 2016; 902: 5–32.

32. WARNAKULASURIYA S. White, red, and mixed lesions of oral mucosa: A clinicopathologic approach to diagnosis. Periodontology, 2000; 80(1): 89–104.

33. WASSERZUG O, et al. Involvement of the maxillary sinus in bisphosphonaterelated osteonecrosis of the jaw: Radiologic aspects. American Journal of Rhinology and Allergy, 2017; 31(1): 36–39.

34. ZHANG L, et al. The Oral Microbiota May Have Influence on Oral Cancer. Frontiers in Cellular and Infection Microbiology, 2020; 9.